Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CryoPort, Inc. - Common Stock (NQ:CYRX)

7.660 +0.220 (+2.96%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CryoPort, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
CryoPort's Earnings: A Preview
CryoPort (NASDAQ:CYRX) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that CryoPort will... 
Via Benzinga
What 4 Analyst Ratings Have To Say About CryoPort
CryoPort (NASDAQ:CYRX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Small Cap Biotechs Regain Momentum
Smaller cap biotech stocks soared off from recent lows looking like a redux of early 2021 when prices were double that of current values. 
Via Talk Markets
CryoPort Earnings Perspective: Return On Invested Capital
According to data from Benzinga Pro, during Q1, CryoPort's (NASDAQ:CYRX) reported sales totaled $52.30 million. Despite a 94.85% increase in earnings, the company posted a loss of $13.40 million. 
Via Benzinga
Expert Ratings for CryoPort
Over the past 3 months, 5 analysts have published their opinion on CryoPort (NASDAQ:CYRX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Earnings Preview For CryoPort
CryoPort (NASDAQ:CYRX) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that CryoPort will... 
Via Benzinga
CryoPort Approves $100M Buyback Program
CryoPort Inc's (NASDAQ: CYRX) Board has authorized a repurchase program. Per the program, CryoPort may repurchase up to $100 million of its outstanding... 
Via Benzinga
CryoPort: Q4 Earnings Insights
CryoPort (NASDAQ:CYRX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
What 5 Analyst Ratings Have To Say About CryoPort
Over the past 3 months, 5 analysts have published their opinion on CryoPort (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
Via Benzinga
Recap: CryoPort Q3 Earnings
CryoPort (NASDAQ:CYRX) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:05 PM. Here's what investors need to know about the announcement. Earnings CryoPort... 
Via Benzinga
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
Biotech Playbook 2021: No Help From Small Caps In Q4
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
Biotech Stocks are Due for a Rally
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums. 
Via Talk Markets
4 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
Looking for Growth in Small and Mid Cap Life Science Stocks
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
CryoPort Inc (CYRX) Q3 2021 Earnings Call Transcript
CYRX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
3 Under-the-Radar COVID Stocks
Some COVID-19 stocks are pretty famous. But other lesser-known names are flying high, too. 
Via The Motley Fool
Chief Financial Officer Of Cryoport Trades $3.8M In Company Stock
Robert Stefanovich, Chief Financial Officer at Cryoport (NASDAQ:CYRX), made a large buy and sell of company shares on October 14, according to a new SEC filing. What Happened: A... 
Via Benzinga
Topics Regulatory Compliance
Biotech Playbook Revisited As Technicals Weaken
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still... 
Via Talk Markets
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day. 
Via Talk Markets
Return on Capital Employed Overview: CryoPort
After pulling data from Benzinga Pro it seems like during Q2, CryoPort (NASDAQ:CYRX) brought in sales totaling $56.19 million. However, earnings decreased 228.2%, resulting in a... 
Via Benzinga
5 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
Cryoport, Mitsubishi Logistics Partner For Temperature-Controlled Supply Chain Solutions
Cryoport Inc (NASDAQ: CYRX) and Mitsubishi Logistics Corporation (MLC) entered a multi-year strategic business alliance to create an integrated... 
Via Benzinga
Vaccine Victory
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson... 
Via Talk Markets
Topics Economy
Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021
Upgrades According to Citigroup, the prior rating for Alcoa Corp (NYSE: 
Via Benzinga
Mid-Cap Biotech Picks: Seasonal Rally Underway
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable. 
Via Talk Markets
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap... 
Via Talk Markets
Biotech Movers During ASCO Week
The biotech sector performed well in a good ASCO week. And many biotech stocks were movers this week as a bullish sentiment took hold sparked by the Biogen Aduhelm approval. 
Via Talk Markets
Not Just GameStop, WallStreetBets' Target Melvin Capital Closed All Public Short Positions In Q1
Hedge fund Melvin Capital Management LP, which was at the heart of the GameStop Corp. (NYSE: GME) short squeeze frenzy earlier this year, closed out of all its public short... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.